Keep up to date with every new upload!

Join free & follow RARECast
Share
  • 1 year ago
Albireo Advances Pipeline for Rare Liver and Gastrointestinal Diseases

Albireo Advances Pipeline for Rare Liver and Gastrointestinal Diseases

PFIC is a rare genetic disorder that causes progressive, life-threatening liver disease. In many cases, PFIC leads to cirrhosis and liver failure within the first 10 years of life. Albireo, a 2008 spin-out of AstraZeneca, is developing bile acid modulators to treat PFIC and other rare pediatric liver diseases and gastrointestinal disorders. We spoke to Ron Cooper, CEO of Albireo, about PFIC, the challenge of developing a therapy for a disease with multiple forms and causes, and the path forward for the company.

Comments